TEAM

CHEEGEE SEE, PHD

25+ years of industry experience in big pharma (GSK, Roche) and SME biotechs (Proteome Sciences, Global Gene Corp, Trajecture) with an excellent working network of C-level decision-makers. Deep oncology clinical trial expertise – Clinical biomarker and experimental medicine leader for Roche’s Herceptin Phase 3 registration trial (ToGA study) for gastric cancer, 2006-2011. Deep oncology discovery research and drug development – Head of Translational Medicine at Global Gene Corp developing novel drug for prostate cancer, 2017. Deep expertise in Precision Medicines, companion diagnostics and biomarker technologies in multiple therapeutic areas – Global Head of Personalized Medicine at Proteome Sciences, 2013-2016. Published book chapter, November 2019 – ‘Clinical Strategies for Developing Next-Generation Cancer Precision Medicines’. Visiting professor at the University of Surrey, teaching MSc module in ‘Pharmaceutical Medicine’, 2015. CheeGee is a visionary strategist who is passionate about translating medical knowledge into transformative treatment options and creating strong and sustainable commercial value.

NATHAN NAGEL 

Mr Nathan Nagel is an entrepreneur with 23 years’ experience on the commercial side of healthcare with 13 years’ experience of being an executive director. Nathan has deep connections and understanding of the markets of the UK, EU, USA and Middle East. He is currently the (1) CEO of the Fratrem Group Ltd, (2) Board Adviser at Quest Prehab (3) Board Adviser at Digistain (4) Faculty at Barts X Medicine digital health program and (5) Mentor to founders on the CRUK Capital Enterprise Cancer Tech Accelerator. His past executive experience includes CEO at Gamlen Tableting Ltd (Pharmaceuticals), Managing Director of Sanyal Bio LLC (Liver disease), CEO of Neuro-Bio Ltd (Neuroscience), CEO of Oncology Pharma Ltd (Market research company), and Managing partner of LifeScience Ventures Ltd (Healthcare Venture Capital). Prior to leading companies Nathan worked in commercial roles for Bayer Diagnostics and Takeda Pharmaceuticals, where he started his career.